Pulmonary complications of tyrosine kinase inhibitors in myeloproliferative disorders

Eur Respir J. 2020 Oct 29;56(4):2002653. doi: 10.1183/13993003.02653-2020. Print 2020 Oct.

Authors

Manuel J Richter¹, Athiththan Yogeswaran¹, Khodr Tello¹

Affiliation

¹ University of Giessen and Marburg Lung Center (UGMLC), member of the German Center for Lung Research (DZL) and of the Excellence Cluster Cardio-Pulmonary Institute (CPI), Giessen, Germany.

PMID: 33122292
DOI: 10.1183/13993003.02653-2020

No abstract available

Publication types

Editorial
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Humans
Janus Kinase 2
Myeloproliferative Disorders* / complications
Myeloproliferative Disorders* / drug therapy
Protein Kinase Inhibitors / adverse effects

Substances

Protein Kinase Inhibitors
Janus Kinase 2